With covid triggering market penetration, Morepen labs betting big on diagnostics devices segment
New Delhi: Drug firm Morepen Laboratories is betting big on the diagnostics devices segment going forward while building its presence in the active pharmaceutical ingredient (API) segment, a top company official said.
The company is also planning an expansion of its pharmaceutical complex at Baddi in Himachal Pradesh and is looking at an investment of over Rs 178 crore for it, he added.
Diagnostic devices currently constitute around 26 per cent of the company's total revenue and in the last four years, Morepen has started manufacturing its diagnostic devices, Morepen Laboratories Chairman and MD Sushil Suri told.
"What has happened is that Covid has triggered and accelerated the market penetration," Suri explained. People are sitting at home, they're scared of getting out. Thus, all of a sudden, the market for these devices has gone up and this has triggered a forward revolution, he added.
"Diagnostic is one sector that is growing. If you remember that before, we barely had one thermometer at home, that too, a mercury thermometer. Usually, there was one thermometer in the whole building that you would borrow if somebody had fallen sick", Suri said.
"But Covid has created fear, so now there are five thermometers at home and everybody's keeping a separate thermometer. There are also other separate devices. People also need BP monitors and gluco monitors. So these have become essential parts of life," he added. The household spend on these digital devices or electronic medical devices, has gone up.
"We are seeing a huge increase in the diagnostic devices market. It is a new market that has opened up and none of the pharma companies is geared for it. But Morepen would rather like to focus more on the direct bond with customers, and empower them with their health in their hands while sitting at home," Suri said. The single largest product in the diagnostics devices portfolio of the company is glucometers, he added.
PTI on Saturday had said that Morepen Labs' board would consider fund raising next week.
PTI reported that the Company had said in a filing that its board would hold a meeting on April 28 to consider and approve proposals for raising funds, through one or more modes including public offer, rights issue, preferential issue among others.
Morepen exports to over 75 countries with certifications from all major regulatory authorities like United States Food and Drug Administration (USFDA) and World Health Organization.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.